Mirabegron Glenmark (Mirabegron)

Mirabegron works by selectively activating β3‑adrenergic receptors on the bladder’s detrusor muscle. This activation relaxes the smooth muscle, expands bladder capacity, and diminishes spontaneous contractions that cause urgency and incontinence.

The dosage of Mirabegron is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. The prescriber determines the appropriate strength and titration schedule.

Mirabegron is classified as Pregnancy Category B, indicating that animal studies have not shown fetal risk, but adequate human data are lacking. It should be used during pregnancy only if the potential benefit justifies the risk. Limited data are available for breastfeeding; a risk‑benefit assessment is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

The primary alternative class for overactive bladder are antimuscarinic drugs, which block muscarinic receptors to reduce bladder contractions. Mirabegron, as a β3‑agonist, offers a different mechanism and is often better tolerated regarding dry mouth and constipation, but may raise blood pressure, a consideration absent with many antimuscarinics.

Mirabegron tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister or container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Mirabegron is taken orally as a tablet, with or without food, according to the prescriber’s instructions. Swallow the tablet whole with water; do not crush, split, or chew unless specifically advised.

Serious adverse events include severe hypertension, urinary retention, tachycardia, angioedema and rare cases of anaphylaxis. Patients should seek immediate medical attention if they experience a sudden rise in blood pressure, inability to urinate, rapid heartbeat, swelling of the face or throat, or signs of an allergic reaction.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with significant cardiovascular disease or those taking strong CYP2D6 or CYP3A4 inhibitors.